Pancreatic cancer

BioLineRx Announces $6 Million Registered Direct Offering

Retrieved on: 
Monday, April 1, 2024
Patient, Sale, Multiple myeloma, Attention, American depositary receipt, ADS, Security (finance), Prospectus, Pancreatic cancer, BioLineRx, Equity capital markets, File, TEL

Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx.

Key Points: 
  • Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx.
  • The offering is expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants), before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be $6.0 million.
  • The offering is being made by the Company pursuant to its shelf registration statement on Form F-3 (File No.

Promising New Data Published on Potential Therapy to Boost Effectiveness of Pancreatic Cancer Treatments

Retrieved on: 
Tuesday, March 26, 2024
Toxicity, Cell, Development, Survival, BLR, Disease, American Cancer Society, PNAC, Research, University, Quality of life, Cancer, IND, Pharmacology, Pancreatic cancer, Mario, Potential, RFU, Therapy, Helix, Person, Pharmaceutical industry

The data points to a promising strategy to boost the effectiveness of existing drugs in pancreatic cancer and other solid-tumor cancers.

Key Points: 
  • The data points to a promising strategy to boost the effectiveness of existing drugs in pancreatic cancer and other solid-tumor cancers.
  • According to the American Cancer Society , some 66,000 persons in the U.S. are diagnosed annually with pancreatic cancer, a disease with a very low survival rate that is projected to take 51,000 lives in 2024.
  • "Finding an approach to use lower doses while maintaining efficacy has been a constant search for cancer treatments."
  • "BLR-100 targets the formation of the protective tumor stroma, a fibrotic-like element that is thought to retard the entry of chemo-therapeutic agents."

Kure It Cancer Research to Grant Cancer Research Project

Retrieved on: 
Friday, March 22, 2024
NCI, Conference, Colorectal cancer, Research, CSSA, Pancreatic cancer, Cancer, MD, Samuel Oschin, Pharmaceutical industry

NEWPORT BEACH, Calif., March 22, 2024 /PRNewswire-PRWeb/ -- Kure It Cancer Research (Kure It) is a nonprofit organization located in Newport Beach. Kure It provides grants to leading medical institutions across the country for research projects that can be translated into new treatments and gives a better understanding in the fight against cancer. A researcher from Cedar Sinai will be receiving a grant for colorectal cancer research.

Key Points: 
  • NEWPORT BEACH, Calif., March 22, 2024 /PRNewswire-PRWeb/ -- Kure It Cancer Research (Kure It) is a nonprofit organization located in Newport Beach.
  • A researcher from Cedar Sinai will be receiving a grant for colorectal cancer research.
  • A significant amount of support for Kure It Cancer Research comes from the self-storage industry.
  • Researcher to be awarded grant at $100,000:
    Jun Gong, MD, is a medical oncologist of the Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, and Urologic Oncology Program in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
International SOS, Disease, Partnership, International, Patient, Hospitality, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
Disease, Partnership, Patient, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers - those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
International SOS, Disease, Partnership, International, Patient, Hospitality, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
Disease, Partnership, Patient, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers - those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Immunovia announces updated financial calendar

Retrieved on: 
Tuesday, March 12, 2024
Risk, Protein, Patient, Nasdaq Stockholm, Pancreatic cancer, Antibody, Pharmaceutical industry

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.

Key Points: 
  • Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.
  • Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
  • Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
  • The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.